A detailed history of Pathstone Holdings, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Pathstone Holdings, LLC holds 20,131 shares of BPMC stock, worth $1.79 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
20,131
Previous 22,216 9.39%
Holding current value
$1.79 Million
Previous $2.39 Million 22.26%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$84.1 - $120.5 $175,348 - $251,242
-2,085 Reduced 9.39%
20,131 $1.86 Million
Q2 2024

Aug 14, 2024

BUY
$85.18 - $108.78 $483,652 - $617,652
5,678 Added 34.33%
22,216 $2.39 Million
Q1 2024

May 13, 2024

BUY
$73.17 - $99.79 $959,917 - $1.31 Million
13,119 Added 383.71%
16,538 $1.57 Million
Q4 2023

Feb 14, 2024

BUY
$43.96 - $92.84 $150,299 - $317,419
3,419 New
3,419 $315,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.31B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.